Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991073 | PMC |
| http://dx.doi.org/10.3389/fmicb.2022.884176 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut virome and its emerging role in inflammatory bowel disease.
World J Methodol
September 2025
Department of Nursing & Midwifery Research, Hamad Medical Corporation, Doha 3050, Qatar.
Inflammatory bowel disease (IBD) is a progressive multifactorial inflammatory disease of the gut. The cause of IBD is yet unknown. Some researchers have shown that genetic factors, environmental factors, and the gut microbiome are significant considerations.
View Article and Find Full Text PDFInteraction between gut virome and microbiota on inflammatory bowel disease.
World J Methodol
September 2025
Department of Surgery, Ascension St Agnes Hospital, Baltimore, MD 21009, United States.
Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic condition marked by recurring gastrointestinal inflammation. While immune, genetic, and environmental factors are well-studied, the gut virome has received less attention. This editorial highlights the work which investigates the gut virome's role in IBD and its interactions with the bacterial microbiome and host immune system.
View Article and Find Full Text PDFEditorial: Phage-based strategies for foodborne pathogen mitigation and detection.
Front Microbiol
July 2025
Laboratory of Biologically Active Compounds, Intercollegiate Faculty of Biotechnology of the University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Gdańsk, Poland.
High-yield bioproduction of virus-free virus-like P4-EKORhE multi-lysin transducing particles as an antimicrobial gene therapeutic.
Front Cell Infect Microbiol
July 2025
Institute for Integrative Systems Biology (I2SysBio), CSIC-Universitat de València, Paterna, Spain.
A description of the construction of the bioengineered P4-EKORhE and a comprehensive method for producing very high yields (up to 10 particles per millilitre) enable the use of virus-like particles to transduce genetically encoded antimicrobials through a combination of synthetic biology and optimised upstream and downstream processing. The final product, a gene-delivered antimicrobial in the form of the multi-lysin cassette, is fully functional before and after packaging within P4-EKORhE particles. The antimicrobial activity of the multi-lysin cassette, characterised by its lysis proteins, was tested in both pure bacterial cultures and a model of phage infection in co-culture with A549 immortalised human epithelial tissue cells.
View Article and Find Full Text PDFDevelopment of an inhalable dry powder of mycobacteriophage D29 using thin-film freeze-drying.
Int J Pharm
September 2025
Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA. Electronic address:
This study aimed to develop a stable dry powder formulation of anti-tuberculosis mycobacteriophage D29 for pulmonary delivery using thin-film freeze-drying (TFFD), which uses rapid freezing and sublimation to generate highly aerosolizable powders. D29 is a shear-sensitive phage with a long, non-contractile tail from the family Siphoviridae, the most common morphotype for mycobacteriophages. Following a design-of-experiments approach, we first screened formulation and process variables for their influence on phage stability.
View Article and Find Full Text PDF